GlaxoSmithKline PLC CEO Andrew Witty was fairly mum about the company’s alleged bribery charges in China during the company’s earnings call July 24. The CEO held a call with media to discuss China specifically, ahead of the company’s normal call, presumably to fend off China questions in advance.
GSK CEO Andrew Witty Under Fire About China During Q2 Call
GSK tried to highlight sales during its Q2 earnings call, but analysts and media grilled the CEO on GSK’s China bribery allegations, which Witty did not expand upon except to say that some execs acted outside of the company’s “processes and controls.”